ZA201702214B - Methods of using interleukin-10 for treating diseases and disorders - Google Patents
Methods of using interleukin-10 for treating diseases and disordersInfo
- Publication number
- ZA201702214B ZA201702214B ZA2017/02214A ZA201702214A ZA201702214B ZA 201702214 B ZA201702214 B ZA 201702214B ZA 2017/02214 A ZA2017/02214 A ZA 2017/02214A ZA 201702214 A ZA201702214 A ZA 201702214A ZA 201702214 B ZA201702214 B ZA 201702214B
- Authority
- ZA
- South Africa
- Prior art keywords
- interleukin
- disorders
- methods
- treating diseases
- diseases
- Prior art date
Links
- 102000003814 Interleukin-10 Human genes 0.000 title 1
- 108090000174 Interleukin-10 Proteins 0.000 title 1
- 208000037765 diseases and disorders Diseases 0.000 title 1
- 229940076144 interleukin-10 Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462067337P | 2014-10-22 | 2014-10-22 | |
| PCT/US2015/056383 WO2016064817A1 (en) | 2014-10-22 | 2015-10-20 | Methods of using interleukin-10 for treating diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201702214B true ZA201702214B (en) | 2019-09-25 |
Family
ID=55761394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2017/02214A ZA201702214B (en) | 2014-10-22 | 2017-03-29 | Methods of using interleukin-10 for treating diseases and disorders |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10143726B2 (Direct) |
| EP (1) | EP3209320B1 (Direct) |
| JP (1) | JP6675394B2 (Direct) |
| KR (1) | KR20170084033A (Direct) |
| CN (1) | CN107106655A (Direct) |
| AU (1) | AU2015336101A1 (Direct) |
| CA (1) | CA2963995A1 (Direct) |
| ES (1) | ES2941234T3 (Direct) |
| MX (1) | MX2017004983A (Direct) |
| WO (1) | WO2016064817A1 (Direct) |
| ZA (1) | ZA201702214B (Direct) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9090691B2 (en) | 2010-09-15 | 2015-07-28 | Applied Molecular Transport Llc | Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences |
| US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
| MX385898B (es) | 2014-05-07 | 2025-03-18 | Applied Molecular Transp Llc | Moleculas de fusion derivadas de la toxina colix para suministro oral de una carga biologicamente activa. |
| US10618970B2 (en) | 2015-02-03 | 2020-04-14 | Armo Biosciences, Inc. | Method of treating cancer with IL-10 and antibodies that induce ADCC |
| US20160361415A1 (en) | 2015-05-28 | 2016-12-15 | Armo Biosciences, Inc. | Methods of Using Interleukin-10 for Treating Diseases and Disorders |
| EP4606387A3 (en) | 2015-08-25 | 2025-11-19 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| KR20180101417A (ko) | 2016-01-11 | 2018-09-12 | 아르모 바이오사이언시스 인코포레이티드 | 항원-특이적 cd8+ t 세포의 제조에서 인터루킨-10 및 이의 사용 방법 |
| EP4083058A3 (en) | 2018-11-07 | 2023-01-11 | Applied Molecular Transport Inc. | Delivery constructs for transcytosis and related methods |
| WO2020096695A1 (en) | 2018-11-07 | 2020-05-14 | Applied Molecular Transport Inc. | Cholix-derived carriers for oral delivery of heterologous payload |
| AU2020219736A1 (en) * | 2019-02-04 | 2021-09-30 | Xenetic Biosciences, Inc. | Methods of using glycopolysialylated therapeutic proteins |
| EP3930687A4 (en) | 2019-02-25 | 2023-06-07 | The University of Chicago | METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS |
| PH12022550330A1 (en) | 2019-08-16 | 2023-02-06 | Applied Molecular Transport Inc | Compositions, formulations, and interleukin production and purification |
| TW202128961A (zh) | 2019-11-20 | 2021-08-01 | 美商安維塔生物科學股份有限公司 | 細胞激素融合蛋白及其醫藥組合物及治療應用 |
| BR112022022899A2 (pt) | 2020-05-12 | 2022-12-20 | Regeneron Pharma | Agonistas de il10 e métodos de uso dos mesmos |
Family Cites Families (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1202840A (en) | 1985-06-10 | 1986-04-08 | Jonathan R. Kleinsasser | Combination wet and dry feeder for animals |
| JPS63152393A (ja) | 1986-07-03 | 1988-06-24 | Takeda Chem Ind Ltd | グリコシル誘導体 |
| US5714585A (en) | 1987-10-26 | 1998-02-03 | Sterling Winthrop, Inc. | Antibodies that are immunoreactive with interleukin-7 |
| US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
| US5032396A (en) | 1989-02-17 | 1991-07-16 | Immunex Corporation | IL-7 to stimulate platelet production |
| US6217857B1 (en) | 1989-06-28 | 2001-04-17 | Schering Corporation | Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof |
| US5231012A (en) | 1989-06-28 | 1993-07-27 | Schering Corporation | Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10) |
| US5229115A (en) | 1990-07-26 | 1993-07-20 | Immunex Corporation | Adoptive immunotherapy with interleukin-7 |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| US5156301A (en) | 1990-12-17 | 1992-10-20 | Imi Cornelius Inc. | Constant ratio post-mix beverage dispensing valve |
| DE69201128T2 (de) | 1991-01-16 | 1995-05-24 | Schering Corp | Behandlung von neoplastischen krankenheiten mit interleukin-10. |
| JPH06505250A (ja) | 1991-01-16 | 1994-06-16 | シェリング・コーポレーション | 癌の養子免疫療法におけるインターロイキン−１０の使用 |
| US5624823A (en) | 1991-11-22 | 1997-04-29 | The General Hospital Corporation | DNA encoding procine interleukin-10 |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| CA2155109A1 (en) | 1993-02-01 | 1994-08-18 | Daniel Abramowicz | Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10 |
| US5328989A (en) | 1993-03-05 | 1994-07-12 | Schering-Plough | Purification of human interleukin-10 from a cell culture medium |
| US5552303A (en) | 1993-03-08 | 1996-09-03 | Immunex Corporation | DNA encoding epithelium-derived T-cell factor |
| WO1994022473A1 (en) | 1993-04-01 | 1994-10-13 | University Of Washington | Use of interleukin 7 to improve vaccine potency |
| US5665345A (en) | 1993-05-24 | 1997-09-09 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of inhibiting viral replication using IL-10 |
| AU681178B2 (en) | 1993-07-26 | 1997-08-21 | Schering Corporation | Agonists and antagonists of human interleukin-10 |
| GB9317618D0 (en) | 1993-08-24 | 1993-10-06 | Royal Free Hosp School Med | Polymer modifications |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
| EP0740552A1 (en) | 1994-01-20 | 1996-11-06 | Schering Corporation | Use of il-10 to stimulate peripheral blood mononuclear cell cytolytic activity |
| US5696234A (en) | 1994-08-01 | 1997-12-09 | Schering Corporation | Muteins of mammalian cytokine interleukin-13 |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US6410008B1 (en) | 1994-12-12 | 2002-06-25 | Beth Israel Hospital Association | Chimeric IL-10 proteins and uses thereof |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5866134A (en) | 1995-03-24 | 1999-02-02 | Schering Corporation | Method for enhancing the antibody response to specific antigens with Interleukin-10 |
| US5770190A (en) | 1995-07-14 | 1998-06-23 | Schering Corporation | Method of treatment of acute leukemia with inteleukin-10 |
| GB2304047A (en) | 1995-08-09 | 1997-03-12 | Univ Manchester | Pharmaceutical compositions containing cytokines |
| US5744451A (en) | 1995-09-12 | 1998-04-28 | Warner-Lambert Company | N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US5759859A (en) | 1996-07-15 | 1998-06-02 | United States Of America As Represented By The Secretary Of The Army | Sensor and method for detecting trace underground energetic materials |
| US5945097A (en) | 1996-09-06 | 1999-08-31 | Schering Corporation | Method for lowering cholesterol levels with interleukin-10 |
| US5989867A (en) | 1996-09-23 | 1999-11-23 | Knappe; Andrea | DNA encoding IL-10-like homologue; related reagents |
| US6660258B1 (en) | 1997-05-09 | 2003-12-09 | Pharma Pacific Pty Ltd | Oromucosal cytokine compositions and uses thereof |
| CA2296770A1 (en) | 1997-07-14 | 1999-01-28 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
| US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
| ATE255422T1 (de) | 1998-01-07 | 2003-12-15 | Debio Rech Pharma Sa | Abbaubare, heterobifunktionelle polyethylenglykolacrylate, sowie damit herstellbare gele und konjugate |
| US6428985B1 (en) | 1998-12-02 | 2002-08-06 | The Regents Of The University Of Michigan | Immunosuppressive structural definition of IL-10 |
| CA2356010A1 (en) | 1998-12-22 | 2000-06-29 | Schering Corporation | Treatment of hepatitis c virus infections with interleukin-10 |
| US7666400B2 (en) | 2005-04-06 | 2010-02-23 | Ibc Pharmaceuticals, Inc. | PEGylation by the dock and lock (DNL) technique |
| WO2001005821A2 (en) | 1999-07-16 | 2001-01-25 | Maria Teresa Bejarano | Viral il-10 for the inhibition of angiogenesis, tumorigenesis and metastasis |
| US6989377B2 (en) | 1999-12-21 | 2006-01-24 | Wisconsin Alumni Research Foundation | Treating vitamin D responsive diseases |
| WO2001058950A1 (en) | 2000-02-11 | 2001-08-16 | Maxygen Aps | Improved interleukin 10 |
| US20030186386A1 (en) | 2000-02-11 | 2003-10-02 | Hansen Christian Karsten | Interleukin 10 |
| WO2002026265A2 (en) | 2000-09-29 | 2002-04-04 | Schering Corporation | Pegylated interleukin-10 |
| JP2002142770A (ja) | 2000-11-08 | 2002-05-21 | Dnavec Research Inc | 循環系への遺伝子送達用パラミクソウイルスベクター |
| US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| EP1234583A1 (en) | 2001-02-23 | 2002-08-28 | F. Hoffmann-La Roche Ag | PEG-conjugates of HGF-NK4 |
| AU2002307497A1 (en) | 2001-04-23 | 2002-11-05 | The Regents Of The University Of California | Methods of using interleukin-7 to modulate physiological processes in mammalian pulmonary fibroblasts |
| GB0212648D0 (en) | 2002-05-31 | 2002-07-10 | Immunoclin Lab Ltd | Treatment with cytokines |
| EP1391513A1 (en) | 2002-08-08 | 2004-02-25 | Cytheris | IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof |
| WO2004022593A2 (en) | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
| US20040142893A1 (en) * | 2002-10-21 | 2004-07-22 | Uichi Ikeda | Methods for treating and preventing vascular disease |
| WO2004044006A1 (en) | 2002-11-14 | 2004-05-27 | Maxygen, Inc. | Conjugates of interleukin-10 and polymers |
| AU2003292137A1 (en) | 2002-11-29 | 2004-06-23 | Maria Grazia Roncarolo | Rapamycin and il-10 for the treatment of immune diseases |
| WO2004056850A2 (en) | 2002-12-19 | 2004-07-08 | Vib Vzw | Mutant proteins showing increased secretion |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| GEP20084487B (en) | 2002-12-26 | 2008-09-25 | Mountain View Pharmaceuticals | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof |
| EP2284180B1 (en) | 2003-03-03 | 2015-09-09 | Dyax Corp. | Uses of peptides that specifically bind HGF receptor (cMET) |
| JP4753867B2 (ja) | 2003-04-15 | 2011-08-24 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | ヒトｉｌ−１８を含むコンジュゲートおよびその置換変異体 |
| US7261882B2 (en) | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
| JPWO2005033307A1 (ja) | 2003-09-30 | 2006-12-14 | 技術研究組合 生物分子工学研究所 | 新規のリフォールディング方法およびその方法によって得られたタンパク質 |
| AU2004293499B2 (en) | 2003-11-28 | 2009-11-26 | The University Of Sydney | Latent phase viral interleukin-10-(VII-10) and uses thereof |
| RU2369616C2 (ru) | 2003-12-30 | 2009-10-10 | Мерк Патент Гмбх | Слитые белки il-7 |
| US20060078942A1 (en) * | 2004-03-10 | 2006-04-13 | Pepgen Corporation | Method of treatment using interferon-tau |
| EA010501B1 (ru) | 2004-03-11 | 2008-10-30 | Фрезениус Каби Дойчланд Гмбх | Конъюгаты гидроксиалкилкрахмала и белка, полученные восстановительным аминированием |
| US20060046961A1 (en) | 2004-09-02 | 2006-03-02 | Mckay William F | Controlled and directed local delivery of anti-inflammatory compositions |
| CN100334112C (zh) | 2004-10-15 | 2007-08-29 | 上海海欣生物技术有限公司 | 人白细胞介素15与Fc融合蛋白 |
| RU2437893C2 (ru) | 2004-12-09 | 2011-12-27 | Мерк Патент Гмбх | Варианты il-7 со сниженной иммуногенностью |
| GB0500643D0 (en) | 2005-01-13 | 2005-02-23 | Renovo Ltd | Medicaments |
| WO2006094530A1 (en) | 2005-03-11 | 2006-09-14 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
| UY29460A1 (es) | 2005-04-08 | 2006-11-30 | Noxxon Pharma Ag | Acidos nucleicos de union a ghrelin |
| US20100028296A1 (en) | 2005-05-02 | 2010-02-04 | Chavez Raymond A | Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease |
| WO2006130580A2 (en) | 2005-05-31 | 2006-12-07 | Avigen, Inc. | Mutant il-10 |
| EP2343363A1 (en) | 2005-07-01 | 2011-07-13 | John Schrader | Methods of isolating cells and generating monoclonal antibodies involving single epitope multiple staining |
| EP1746161A1 (en) | 2005-07-20 | 2007-01-24 | Cytheris | Glycosylated IL-7, preparation and uses |
| ES2357152T3 (es) | 2005-10-04 | 2011-04-19 | Zymogenetics, L.L.C. | Producción y purificación de il-29. |
| WO2007061657A2 (en) | 2005-11-14 | 2007-05-31 | The Brigham & Women's Hospital, Inc. | Interleukin-10 compositions for the treatment of adenocarcinomas |
| US7868139B2 (en) | 2006-01-24 | 2011-01-11 | Uab Research Foundation | Compositions and methods for the identification and treatment of immune-mediated inflammatory diseases |
| CA2664304C (en) * | 2006-09-28 | 2017-08-22 | Schering Corporation | Use of pegylated il-10 to treat cancer |
| JP2010506166A (ja) | 2006-10-05 | 2010-02-25 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | デング熱の診断及び治療 |
| US8247370B2 (en) | 2006-12-04 | 2012-08-21 | Promedior, Inc. | Conjoint therapy for treating fibrotic diseases |
| CA2989778C (en) | 2007-01-19 | 2020-06-30 | Kai Pharmaceuticals, Inc. | Method of modifying peptide compositions |
| WO2009016043A2 (en) | 2007-07-31 | 2009-02-05 | Affibody Ab | New albumin binding compositions, methods and uses |
| WO2009036568A1 (en) | 2007-09-19 | 2009-03-26 | University Health Network | Methods and compositions for treating tumors and viral infections |
| EP2200649A4 (en) | 2007-10-19 | 2012-09-26 | Univ California | COMPOSITIONS AND METHODS FOR IMPROVING INFLAMMATION OF SN, PSYCHOSIS, DELI, PTSD OR PTSD |
| GB0724231D0 (en) | 2007-12-12 | 2008-01-30 | Renono Ltd | Methods for inhibiting scarring |
| JP2011525616A (ja) * | 2008-05-29 | 2011-09-22 | ブリストル−マイヤーズ スクイブ カンパニー | 共刺激経路の調節に対する患者応答を予測するための方法 |
| WO2010022227A1 (en) * | 2008-08-20 | 2010-02-25 | Schering Corporation | Methods for monitoring il-10 therapy |
| PL2379115T3 (pl) | 2008-12-17 | 2018-03-30 | Merck Sharp & Dohme Corp. | Wytwarzanie i zastosowania mono- i di-peg il-10 |
| BR112012008665A2 (pt) | 2009-10-12 | 2016-11-22 | Pfizer | tratamento de câncer |
| ES2700230T3 (es) | 2009-10-30 | 2019-02-14 | Albumedix Ltd | Variantes de albúmina |
| BR112012032206A2 (pt) | 2010-06-16 | 2016-10-04 | Abbvie Inc | comparações de amostras de proteínas |
| EP2590993B1 (en) | 2010-07-09 | 2015-05-06 | Affibody AB | Polypeptides |
| US8759617B2 (en) | 2010-09-21 | 2014-06-24 | National Institute Of Agrobiological Sciences | Method for extraction and purification of recombinant proteins from transgenic plants |
| EA032917B1 (ru) | 2010-09-28 | 2019-08-30 | Амилин Фармасьютикалс, Ллк | Сконструированные полипептиды, характеризующиеся увеличенной продолжительностью действия |
| CN106986940A (zh) | 2010-09-28 | 2017-07-28 | 艾米琳制药有限责任公司 | 具有增强的作用持续时间的工程化多肽 |
| MX362591B (es) * | 2010-11-05 | 2019-01-25 | Novartis Ag | Uso de antagonistas de il-17. |
| CN110200997A (zh) | 2011-03-23 | 2019-09-06 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
| CN102145178B (zh) | 2011-04-15 | 2012-09-26 | 北京凯因科技股份有限公司 | Peg化白介素15 |
| EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| EP2807266B1 (en) | 2012-01-26 | 2020-01-15 | Amgen Inc. | Growth differentiation factor 15 (gdf-15) polypeptides |
| US20150038678A1 (en) | 2012-02-29 | 2015-02-05 | Ambrx, Inc. | Interleukin-10 Polypeptide Conjugates and Their Uses |
| WO2013169971A1 (en) | 2012-05-10 | 2013-11-14 | Bristol-Myers Squibb Company | Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients |
| CA2908198A1 (en) | 2013-04-18 | 2014-10-23 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| WO2014176373A2 (en) | 2013-04-24 | 2014-10-30 | Armo Biosciences, Inc. | Interleukin-10 compositions and uses thereof |
| ES2688206T3 (es) | 2013-06-17 | 2018-10-31 | Armo Biosciences, Inc. | Procedimiento de evaluación de la identidad y la estabilidad de proteínas |
| JP6509867B2 (ja) | 2013-08-30 | 2019-05-08 | アルモ・バイオサイエンシーズ・インコーポレイテッド | 疾患及び障害を治療するためにインターロイキン−１０を使用する方法 |
| WO2015070060A1 (en) | 2013-11-11 | 2015-05-14 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| WO2015108785A1 (en) | 2014-01-15 | 2015-07-23 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| EP3097117B1 (en) | 2014-01-21 | 2023-10-04 | Novartis Ag | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| MA39711A (fr) | 2014-04-03 | 2015-10-08 | Nektar Therapeutics | Conjugués d'une fraction d'il-15 et d'un polymère |
| WO2015187295A2 (en) * | 2014-06-02 | 2015-12-10 | Armo Biosciences, Inc. | Methods of lowering serum cholesterol |
| US20170362291A1 (en) | 2014-12-23 | 2017-12-21 | Armo Biosciences, Inc. | Methods of Improving Yield in Recombinant Protein Production |
| WO2016145388A1 (en) | 2015-03-11 | 2016-09-15 | Nektar Therapeutics | Conjugates of an il-7 moiety and an polymer |
| US20160361415A1 (en) | 2015-05-28 | 2016-12-15 | Armo Biosciences, Inc. | Methods of Using Interleukin-10 for Treating Diseases and Disorders |
-
2015
- 2015-10-20 ES ES15852286T patent/ES2941234T3/es active Active
- 2015-10-20 JP JP2017521564A patent/JP6675394B2/ja active Active
- 2015-10-20 KR KR1020177011082A patent/KR20170084033A/ko not_active Withdrawn
- 2015-10-20 MX MX2017004983A patent/MX2017004983A/es unknown
- 2015-10-20 CA CA2963995A patent/CA2963995A1/en not_active Abandoned
- 2015-10-20 WO PCT/US2015/056383 patent/WO2016064817A1/en not_active Ceased
- 2015-10-20 CN CN201580069348.9A patent/CN107106655A/zh active Pending
- 2015-10-20 EP EP15852286.2A patent/EP3209320B1/en active Active
- 2015-10-20 US US15/513,825 patent/US10143726B2/en active Active
- 2015-10-20 AU AU2015336101A patent/AU2015336101A1/en not_active Abandoned
-
2017
- 2017-03-29 ZA ZA2017/02214A patent/ZA201702214B/en unknown
-
2018
- 2018-10-23 US US16/168,345 patent/US10653751B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20190046613A1 (en) | 2019-02-14 |
| JP6675394B2 (ja) | 2020-04-01 |
| MX2017004983A (es) | 2017-11-13 |
| EP3209320B1 (en) | 2023-03-08 |
| EP3209320A1 (en) | 2017-08-30 |
| US10653751B2 (en) | 2020-05-19 |
| ES2941234T3 (es) | 2023-05-19 |
| CN107106655A (zh) | 2017-08-29 |
| KR20170084033A (ko) | 2017-07-19 |
| EP3209320A4 (en) | 2018-07-18 |
| WO2016064817A1 (en) | 2016-04-28 |
| AU2015336101A1 (en) | 2017-04-20 |
| JP2017533201A (ja) | 2017-11-09 |
| US10143726B2 (en) | 2018-12-04 |
| CA2963995A1 (en) | 2016-04-28 |
| US20170246252A1 (en) | 2017-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285151B1 (en) | Methods for the treatment of fgf21-related disorders | |
| ZA201901279B (en) | Compositions and methods for treatment of neurological disorders | |
| ZA201602839B (en) | Methods of using interleukin-10 for treating diseases and disorders | |
| ZA201702214B (en) | Methods of using interleukin-10 for treating diseases and disorders | |
| IL253244B1 (en) | Methods for treating retinal diseases | |
| IL248732A0 (en) | Compounds for the treatment of ophthalmological diseases and disorders | |
| EP2986306A4 (en) | METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING | |
| HUE060671T2 (hu) | Eljárás fibrotikus betegségek kezelésére | |
| IL269302A (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
| GB201701673D0 (en) | Methods of well treatment | |
| GB201405232D0 (en) | Apparatus and methods for the treatment of ocular disorders | |
| SG11201609993YA (en) | Treatment of immune disorders | |
| IL251262A0 (en) | Methods for treating traumatic brain injury | |
| IL320533A (en) | Methods and compositions for treating disorders and diseases involving RDH12 | |
| EP3038642A4 (en) | Methods of using interleukin-10 for treating diseases and disorders | |
| SG11201704829QA (en) | Methods and compositions for treating brain diseases | |
| ZA201705877B (en) | Method of treating diseases | |
| GB201412578D0 (en) | Treatment of neurological diseases | |
| EP3154616A4 (en) | Methods and apparatus for treatment of respiratory disorders | |
| GB201416832D0 (en) | Methods of treatment | |
| GB201408387D0 (en) | Treatment of respiratory disorders | |
| IL253847A0 (en) | Methods of treating diseases | |
| GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
| IL251736B (en) | Methods and compositions for the treatment of radiation-related disorders | |
| EP3151824A4 (en) | Methods of treating neurodevelopmental diseases and disorders |